<DOC>
	<DOCNO>NCT03018444</DOCNO>
	<brief_summary>The primary objective present study evaluate effect HMG-CoA reductase inhibition 14 day postprandial plasma GLP-1 response healthy individual . Secondary objective include evaluation HMG-CoA reductase inhibition postprandial glucose tolerance , gallbladder emptying , gastric emptying , plasma response lipid , bile acid pancreatic enteric hormone know influence glucose metabolism appetite , faecal content bile acid gut microbiota composition .</brief_summary>
	<brief_title>The Effect HMG-CoA Reductase Inhibition Postprandial GLP-1 Secretion</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Body mass index ( BMI ) &gt; 18.5 kg/m2 &lt; 35 kg/m2 Caucasian ethnicity Normal haemoglobin Glycated haemoglobin ( HbA1c ) &lt; 43 mmol/mol Fasting plasma glucose &lt; 6 mmol/l Informed write consent Diabetes Firstdegree relatives diabetes ( type 1 diabetes type 2 diabetes ) Liver disease ( serum alanine aminotransferase ( ALAT ) and/or serum aspartate aminotransferase ( ASAT ) &gt; 2 time normal value ) history hepatobiliary disorder Gastrointestinal disease , previous intestinal resection , cholecystectomy major intraabdominal surgery Reduced kidney function nephropathy ( estimate glomerular filtration rate ( eGFR ) &lt; 60 ml/min/1.73 m2 ( base serum creatinine ) and/or albuminuria Taking kind medicine regular basis Intake antibiotic two month prior study Active recent malignant disease Any treatment condition require acute subacute medical surgical intervention Any condition consider incompatible participation investigator If subject receive antibiotic treatment include study exclude</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>